Payton Pritchard: Everything you need to know

Payton Pritchard

#11 PG

Boston Celtics

Status

GTD - Foot - Plantar Fasciitis Expected Return: 2026-04-18

STATS

Career Averages

PTS

REB

AST

BLK

STL

10.6

3.0

0.1

0.6

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	79	50	32.4	17.0	3.9	5.2	0.1	0.7	1.4	5	0	2.7	7.1	37.7%	3.7	6.7	55.6%	6.4	13.8	46.4%	1.5	1.7	89.0%	0.9	3.1	1.5	3.7	+426	58.4%
2024-25	80	3	28.4	14.3	3.8	3.5	0.2	0.9	1.0	5	0	3.2	7.8	40.7%	1.9	3.0	64.2%	5.1	10.8	47.2%	0.9	1.1	84.5%	1.3	2.6	1.5	3.4	+430	63.3%
2023-24	82	5	22.3	9.6	3.2	3.4	0.1	0.5	0.7	3	0	1.8	4.7	38.5%	1.8	3.1	59.3%	3.6	7.7	46.8%	0.6	0.7	82.1%	0.9	2.4	1.3	4.6	+449	59.7%
2022-23	48	3	13.4	5.6	1.8	1.3	0.0	0.3	0.8	1	1	1.2	3.2	36.4%	0.9	1.9	49.5%	2.1	5.1	41.2%	0.3	0.3	75.0%	0.5	1.3	0.8	1.6	+12	53.6%
2021-22	71	2	14.1	6.2	1.9	2.0	0.1	0.4	0.6	0	0	1.4	3.5	41.2%	0.8	1.8	46.1%	2.3	5.3	42.9%	0.3	0.3	100.0%	0.5	1.4	0.9	3.4	+64	57.8%
2020-21	66	4	19.2	7.7	2.4	1.8	0.1	0.6	0.8	0	0	1.5	3.8	41.1%	1.2	2.6	48.2%	2.8	6.3	44.0%	0.6	0.7	88.9%	0.5	1.9	1.6	2.3	+40	58.2%
Career	426	67	22.5	10.6	3.0	3.0	0.1	0.6	0.9	14	1	2.0	5.2	39.4%	1.8	3.3	55.6%	3.9	8.5	45.7%	0.7	0.8	86.9%	0.8	2.2	1.3	3.3	+1421	59.4%

Career Averages

PTS

REB

AST

BLK

STL

6.0

1.8

1.7

0.0

0.3

Year	GP	MIN	PTS	REB	AST	BLK	STL	TO	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2024-25	11	27.5	11.9	2.3	1.5	0.0	0.5	0.8	2.5	6.1	40.3%	1.6	2.9	56.3%	4.1	9.0	45.5%	1.3	1.5	82.4%	0.8	1.5	1.7	1.9	+72	61.5%
2023-24	19	18.7	6.4	1.9	2.1	0.0	0.2	0.7	1.2	3.2	38.3%	1.1	2.4	46.7%	2.3	5.5	41.9%	0.6	0.6	91.7%	0.7	1.2	1.2	2.9	+28	55.3%
2022-23	10	5.7	3.2	0.6	1.1	0.0	0.1	0.5	0.4	1.0	40.0%	0.8	1.2	66.7%	1.2	2.2	54.5%	0.4	0.5	80.0%	0.0	0.6	0.3	2.2	+8	66.1%
2021-22	24	12.9	4.8	1.9	1.6	0.1	0.3	0.4	1.0	3.0	33.3%	0.8	1.3	63.3%	1.8	4.3	42.2%	0.2	0.3	66.7%	0.4	1.5	1.0	4.2	+56	54.5%
2020-21	5	13.4	3.4	1.8	2.4	0.0	0.4	0.6	0.6	2.0	30.0%	0.6	1.4	42.9%	1.2	3.4	35.3%	0.4	0.4	100.0%	0.4	1.4	0.8	4.0	-13	47.5%
Career	69	15.8	6.0	1.8	1.7	0.0	0.3	0.6	1.2	3.2	37.0%	1.0	1.8	54.8%	2.2	5.0	43.5%	0.5	0.6	83.3%	0.5	1.3	1.0	3.0	+151	57.2%

Preseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
10/15	TOR	W 110-108	31	10	3	10	0	2	0	8	0	0.0%	3	1	33.3%	11	1	9.1%	8	8	100.0%	0	3	0.0	+19	0	19	34.4%
10/12	CLE	W 138-107	23	14	5	2	0	2	1	5	2	40.0%	6	4	66.7%	11	6	54.5%	0	0	0.0%	0	5	2.0	+26	2	14	63.6%
10/10	TOR	L 107-105	25	19	4	3	0	1	3	8	3	37.5%	9	4	44.4%	17	7	41.2%	2	2	100.0%	1	3	1.0	+8	0	16	53.1%
Preseason Totals			26.9	14.3	4.0	5.0	0.0	1.7	1.3	7.0	1.7	23.8%	6.0	3.0	50.0%	13.0	4.7	35.9%	3.3	3.3	100.0%	0.3	3.7	3.8	+53	0.7	18.0	49.5%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/9	NYK	L 112-106	35	23	3	6	0	0	2	8	3	37.5%	12	7	58.3%	20	10	50.0%	0	0	0.0%	2	1	3.0	+4	1	19	57.5%
4/7	CHA	W 113-102	29	12	4	3	0	0	2	7	4	57.1%	1	0	0.0%	8	4	50.0%	0	0	0.0%	2	2	1.5	+5	2	13	75.0%
4/5	TOR	W 115-101	30	17	1	3	0	3	1	3	1	33.3%	9	6	66.7%	12	7	58.3%	2	2	100.0%	0	1	3.0	+9	2	18	66.0%
4/3	MIL	W 133-101	26	16	3	6	0	0	1	6	2	33.3%	6	5	83.3%	12	7	58.3%	0	0	0.0%	1	2	6.0	+2	0	20	66.7%
4/1	MIA	W 147-129	31	14	3	4	1	0	0	7	4	57.1%	2	1	50.0%	9	5	55.6%	0	0	0.0%	2	1	0.0	+20	2	16	77.8%
3/30	ATL	L 112-102	25	16	2	0	0	0	1	6	4	66.7%	8	2	25.0%	14	6	42.9%	0	0	0.0%	0	2	0.0	-19	1	8	57.1%
3/29	CHA	W 114-99	37	28	6	6	0	1	2	6	2	33.3%	12	8	66.7%	18	10	55.6%	6	6	100.0%	1	5	3.0	+12	3	31	67.8%
3/27	ATL	W 109-102	34	36	7	4	0	0	5	11	6	54.5%	12	7	58.3%	23	13	56.5%	4	4	100.0%	3	4	0.8	+26	2	32	72.7%
3/25	OKC	W 119-109	32	14	2	1	1	0	1	6	4	66.7%	5	1	20.0%	11	5	45.5%	0	0	0.0%	0	2	1.0	+11	2	9	63.6%
3/22	MIN	L 102-92	27	10	1	3	0	1	1	6	2	33.3%	5	2	40.0%	11	4	36.4%	0	0	0.0%	0	1	3.0	-11	1	6	45.5%
3/20	MEM	W 117-112	31	19	6	3	0	0	4	10	3	30.0%	3	2	66.7%	13	5	38.5%	6	6	100.0%	1	5	0.8	+9	3	16	60.7%
3/18	GSW	W 120-99	30	19	0	7	0	1	1	7	3	42.9%	9	5	55.6%	16	8	50.0%	0	0	0.0%	0	0	7.0	+25	2	16	59.4%
3/16	PHX	W 120-112	37	19	4	6	0	1	2	9	5	55.6%	4	1	25.0%	13	6	46.2%	2	2	100.0%	1	3	3.0	+8	4	18	68.4%
3/14	WAS	W 111-100	30	4	4	4	1	2	0	4	0	0.0%	7	2	28.6%	11	2	18.2%	0	0	0.0%	0	4	0.0	-6	1	5	18.2%
3/12	OKC	L 104-102	38	14	4	4	0	0	2	9	2	22.2%	8	4	50.0%	17	6	35.3%	0	0	0.0%	1	3	2.0	-7	0	11	41.2%
3/8	CLE	W 109-98	34	18	3	7	0	1	2	6	2	33.3%	6	5	83.3%	12	7	58.3%	2	2	100.0%	1	2	3.5	+18	2	22	69.9%
3/6	DAL	W 120-100	33	18	7	6	2	0	1	8	2	25.0%	9	6	66.7%	17	8	47.1%	0	0	0.0%	2	5	6.0	+19	0	21	52.9%
3/4	CHA	L 118-89	24	0	2	0	0	0	2	5	0	0.0%	1	0	0.0%	6	0	0.0%	0	0	0.0%	0	2	0.0	-14	2	7	0.0%
3/2	MIL	W 108-81	33	25	4	9	0	0	1	10	5	50.0%	13	5	38.5%	23	10	43.5%	0	0	0.0%	2	2	9.0	+15	1	22	54.3%
3/1	PHI	W 114-98	27	0	3	5	0	1	2	4	0	0.0%	0	0	0.0%	4	0	0.0%	0	0	0.0%	0	3	2.5	+7	1	2	0.0%
2/27	BKN	W 148-111	28	22	0	5	0	1	1	5	4	80.0%	7	5	71.4%	12	9	75.0%	0	0	0.0%	0	0	5.0	+40	1	24	91.7%
2/25	DEN	L 103-84	27	3	3	4	0	2	0	3	1	33.3%	3	0	0.0%	6	1	16.7%	0	0	0.0%	0	3	0.0	-13	3	4	25.0%
2/24	PHX	W 97-81	34	8	6	4	0	1	3	5	0	0.0%	8	2	25.0%	13	2	15.4%	4	4	100.0%	1	5	1.3	+11	1	5	27.1%
2/22	LAL	W 111-89	37	30	4	8	0	0	4	9	6	66.7%	5	4	80.0%	14	10	71.4%	4	4	100.0%	2	2	2.0	+21	4	33	95.2%
2/19	GSW	W 121-110	32	26	6	7	0	1	4	11	6	54.5%	7	4	57.1%	18	10	55.6%	0	0	0.0%	0	6	1.8	+5	0	29	72.2%
2/11	CHI	W 124-105	33	26	5	8	0	2	5	8	3	37.5%	10	8	80.0%	18	11	61.1%	2	1	50.0%	0	5	1.6	+13	0	30	68.9%
2/8	NYK	L 111-89	30	6	2	7	0	2	1	6	1	16.7%	3	1	33.3%	9	2	22.2%	1	1	100.0%	2	0	7.0	-27	0	10	31.8%
2/6	MIA	W 98-96	35	24	1	1	0	1	2	6	4	66.7%	9	4	44.4%	15	8	53.3%	4	4	100.0%	0	1	0.5	+4	3	18	71.6%
2/4	HOU	W 114-93	33	27	3	7	0	0	1	10	5	50.0%	10	4	40.0%	20	9	45.0%	5	4	80.0%	1	2	7.0	+17	0	25	60.8%
2/3	DAL	W 110-100	34	26	4	7	0	0	2	8	2	25.0%	12	10	83.3%	20	12	60.0%	0	0	0.0%	0	4	3.5	+0	1	25	65.0%
2/1	MIL	W 107-79	26	7	3	5	0	0	0	4	1	25.0%	4	1	25.0%	8	2	25.0%	2	2	100.0%	0	3	0.0	+10	1	9	39.4%
1/30	SAC	W 112-93	32	29	2	8	0	0	2	6	5	83.3%	10	7	70.0%	16	12	75.0%	0	0	0.0%	0	2	4.0	+20	1	33	90.6%
1/28	ATL	L 117-106	27	12	4	0	0	0	0	3	0	0.0%	8	5	62.5%	11	5	45.5%	2	2	100.0%	0	4	0.0	-30	1	10	50.5%
1/26	POR	W 102-94	34	23	4	3	0	0	0	11	5	45.5%	5	3	60.0%	16	8	50.0%	4	2	50.0%	1	3	0.0	+23	1	21	64.8%
1/24	CHI	L 114-111	29	10	3	7	0	0	1	3	1	33.3%	7	3	42.9%	10	4	40.0%	1	1	100.0%	0	3	7.0	-4	0	13	47.9%
1/23	BKN	W 130-126	40	32	4	4	0	0	1	11	6	54.5%	13	7	53.8%	24	13	54.2%	0	0	0.0%	1	3	4.0	-3	3	25	66.7%
1/21	IND	W 119-104	33	10	5	8	0	1	2	5	1	20.0%	7	3	42.9%	12	4	33.3%	1	1	100.0%	1	4	4.0	+26	1	14	40.2%
1/19	DET	L 104-103	33	17	3	3	0	0	2	6	3	50.0%	2	2	100.0%	8	5	62.5%	5	4	80.0%	1	2	1.5	+2	3	15	83.3%
1/15	MIA	W 119-114	24	2	3	8	1	1	1	2	0	0.0%	2	1	50.0%	4	1	25.0%	0	0	0.0%	1	2	8.0	-20	1	11	25.0%
1/12	IND	L 98-96	37	23	4	8	0	2	0	7	3	42.9%	15	7	46.7%	22	10	45.5%	0	0	0.0%	1	3	0.0	+1	0	24	52.3%
1/10	SAS	L 100-95	28	4	5	4	0	1	0	3	0	0.0%	6	2	33.3%	9	2	22.2%	0	0	0.0%	0	5	0.0	-1	0	7	22.2%
1/9	TOR	W 125-117	29	27	5	8	1	0	1	5	3	60.0%	14	9	64.3%	19	12	63.2%	0	0	0.0%	0	5	8.0	+11	0	33	71.1%
1/7	DEN	L 114-110	33	17	5	2	0	2	0	6	1	16.7%	7	4	57.1%	13	5	38.5%	6	6	100.0%	3	2	0.0	-5	2	19	54.3%
1/5	CHI	W 115-101	31	21	6	5	0	1	0	7	4	57.1%	10	4	40.0%	17	8	47.1%	1	1	100.0%	0	6	0.0	+11	1	24	60.2%
1/3	LAC	W 146-115	39	12	4	8	0	1	0	3	2	66.7%	7	3	42.9%	10	5	50.0%	0	0	0.0%	0	4	0.0	+27	2	18	60.0%
1/1	SAC	W 120-106	30	16	3	6	1	1	2	8	2	25.0%	5	4	80.0%	13	6	46.2%	2	2	100.0%	2	1	3.0	+4	2	18	57.6%
12/30	UTA	W 129-119	35	18	4	6	0	1	0	7	1	14.3%	8	7	87.5%	15	8	53.3%	1	1	100.0%	0	4	0.0	+1	1	21	58.3%
12/28	POR	L 114-108	37	9	5	5	0	2	2	8	3	37.5%	2	0	0.0%	10	3	30.0%	0	0	0.0%	0	5	2.5	+2	0	12	45.0%
12/26	IND	W 140-122	37	29	9	5	0	1	3	8	3	37.5%	9	7	77.8%	17	10	58.8%	8	6	75.0%	2	7	1.7	+8	3	33	70.7%
12/22	IND	W 103-95	32	11	3	5	0	2	3	4	1	25.0%	8	3	37.5%	12	4	33.3%	2	2	100.0%	1	2	1.7	-6	3	9	42.7%
12/20	TOR	W 112-96	37	33	7	10	0	0	1	9	4	44.4%	15	9	60.0%	24	13	54.2%	3	3	100.0%	2	5	10.0	+4	0	41	65.2%
12/19	MIA	W 129-116	26	9	4	4	0	2	0	8	2	25.0%	0	0	0.0%	8	2	25.0%	4	3	75.0%	1	3	0.0	-2	1	13	46.1%
12/15	DET	L 112-105	35	12	4	5	0	0	1	8	2	25.0%	6	3	50.0%	14	5	35.7%	0	0	0.0%	0	4	5.0	-1	0	11	42.9%
12/11	MIL	L 116-101	30	11	5	7	0	0	0	11	3	27.3%	3	1	33.3%	14	4	28.6%	0	0	0.0%	1	4	0.0	-21	1	12	39.3%
12/7	TOR	W 121-113	37	15	4	6	0	1	0	8	3	37.5%	4	3	75.0%	12	6	50.0%	0	0	0.0%	1	3	0.0	+18	1	19	62.5%
12/5	LAL	W 126-105	30	15	2	6	0	1	2	7	3	42.9%	6	3	50.0%	13	6	46.2%	0	0	0.0%	0	2	3.0	+15	2	12	57.7%
12/4	WAS	W 146-101	32	20	6	8	0	1	1	9	3	33.3%	12	5	41.7%	21	8	38.1%	1	1	100.0%	5	1	8.0	+27	1	18	46.6%
12/2	NYK	W 123-117	30	10	4	3	0	1	1	7	1	14.3%	6	3	50.0%	13	4	30.8%	1	1	100.0%	0	4	3.0	+0	3	6	37.2%
11/30	CLE	W 117-115	30	42	3	3	0	0	2	11	6	54.5%	11	9	81.8%	22	15	68.2%	6	6	100.0%	0	3	1.5	+10	3	39	85.2%
11/29	MIN	L 119-115	30	9	5	4	1	1	0	8	1	12.5%	6	3	50.0%	14	4	28.6%	0	0	0.0%	1	4	0.0	-12	0	10	32.1%
11/26	DET	W 117-114	34	16	5	2	1	0	1	7	4	57.1%	3	1	33.3%	10	5	50.0%	2	2	100.0%	1	4	2.0	+1	1	20	73.5%
11/23	ORL	W 138-129	33	19	5	8	0	2	1	4	1	25.0%	12	8	66.7%	16	9	56.3%	0	0	0.0%	2	3	8.0	+15	1	24	59.4%
11/21	BKN	L 113-105	34	13	3	4	0	0	1	9	3	33.3%	4	2	50.0%	13	5	38.5%	0	0	0.0%	1	2	4.0	-13	1	11	50.0%
11/18	BKN	W 113-99	35	22	10	5	0	0	3	12	5	41.7%	4	1	25.0%	16	6	37.5%	5	5	100.0%	2	8	1.7	+11	1	26	60.4%
11/16	LAC	W 121-118	33	30	3	2	0	0	0	13	8	61.5%	3	2	66.7%	16	10	62.5%	2	2	100.0%	1	2	0.0	-15	1	31	88.9%
11/12	MEM	W 131-95	30	24	6	9	0	0	0	10	5	50.0%	5	3	60.0%	15	8	53.3%	4	3	75.0%	0	6	0.0	+42	1	32	71.6%
11/11	PHI	L 102-100	31	5	3	3	0	1	1	5	1	20.0%	4	1	25.0%	9	2	22.2%	0	0	0.0%	1	2	3.0	-9	2	1	27.8%
11/9	ORL	W 111-107	33	5	5	5	0	0	3	6	1	16.7%	2	1	50.0%	8	2	25.0%	0	0	0.0%	0	5	1.7	+2	4	2	31.3%
11/7	ORL	L 123-110	31	27	2	4	0	1	3	8	5	62.5%	8	3	37.5%	16	8	50.0%	8	6	75.0%	0	2	1.3	-11	3	19	69.2%
11/5	WAS	W 136-107	23	18	2	5	0	0	2	6	2	33.3%	6	5	83.3%	12	7	58.3%	2	2	100.0%	1	1	2.5	+36	2	19	69.9%
11/3	UTA	L 105-103	34	18	5	3	0	0	1	11	4	36.4%	4	3	75.0%	15	7	46.7%	0	0	0.0%	1	4	3.0	+2	3	15	60.0%
11/1	HOU	L 128-101	26	14	1	4	0	1	1	4	1	25.0%	6	4	66.7%	10	5	50.0%	3	3	100.0%	1	0	4.0	-19	1	15	61.8%
10/31	PHI	W 109-108	33	15	2	5	0	2	1	9	1	11.1%	8	6	75.0%	17	7	41.2%	0	0	0.0%	1	1	5.0	-4	0	12	44.1%
10/29	CLE	W 125-105	31	10	3	10	0	2	1	8	1	12.5%	5	3	60.0%	13	4	30.8%	2	1	50.0%	0	3	10.0	+18	2	13	36.0%
10/27	NOP	W 122-90	30	18	3	8	0	1	1	7	2	28.6%	8	5	62.5%	15	7	46.7%	2	2	100.0%	2	1	8.0	+27	2	21	56.7%
10/26	DET	L 119-113	33	21	10	4	0	0	1	8	2	25.0%	8	6	75.0%	16	8	50.0%	5	3	60.0%	3	7	4.0	-4	1	26	57.7%
10/24	NYK	L 105-95	35	8	5	6	0	1	1	7	1	14.3%	3	1	33.3%	10	2	20.0%	3	3	100.0%	0	5	6.0	-7	3	9	35.3%
10/22	PHI	L 117-116	37	16	5	2	0	2	2	7	1	14.3%	7	5	71.4%	14	6	42.9%	4	3	75.0%	2	3	1.0	+6	3	14	50.8%
Regular Season Totals			32.4	17.0	4.0	5.1	0.1	0.7	1.4	7.1	2.7	37.4%	6.7	3.7	55.7%	13.8	6.4	46.3%	1.7	1.5	88.8%	0.9	3.1	3.7	+397	1.5	19.5	58.3%

Payton Pritchard: Breaking News

Pritchard (foot) has been ruled out for Sunday's game against Orlando, Justin Turpin of WEEI.com reports. Pritchard drew the doubtful tag for Sunday's regular-season finale due to left foot plantar fasciitis, and he'll indeed be sidelined as the Celtics prepare for their playoff run. The sixth-year guard started in a career-high 50 regular-season games, but he returned to a bench role in early February after Anfernee Simons (wrist) was traded to the Bulls in exchange for Nikola Vucevic (finger). Pritchard was still effective in his sixth-man role, and across 31 outings (two starts) since Feb. 3, he averaged 17.5 points, 5.0 assists, 3.4 rebounds and 2.9 threes over 32.0 minutes per game while connecting on 41.7 percent of his field-goal attempts from beyond the arc. Dalano Banton, Max Shulga and Baylor Scheierman will all handle more responsibilities against Orlando in Pritchard's absence.

Pritchard is listed as doubtful for Sunday's regular-season finale against the Magic due to left foot plantar fasciitis, Taylor Snow of the Celtics' official site reports. The Celtics locked their spot as the No. 2 seed in the Eastern Conference after their blowout win against the Pelicans on Friday. With nothing to play for Sunday, Boston will rest its entire starting lineup, and it looks like Pritchard will also not play against Orlando. If that's indeed the case, Pritchard will end the 2025-26 regular season averaging career highs in points (17.0), assists (5.2), rebounds (3.9) and minutes (32.4). Max Shulga, Dalano Banton, Baylor Scheierman, Hugo Gonzalez and other deep rotational players for the Celtics should all see extended action Sunday.

Pritchard ended Friday's 144-118 victory over the Pelicans with 21 points (7-14 FG, 5-9 3Pt, 2-2 FT), three rebounds, 10 assists and one steal in 30 minutes. Pritchard posted his fifth double-double of the season Friday, taking advantage of some extra usage left behind by the absence of Jayson Tatum (Achilles). Over his last seven contests, Pritchard has averaged 17.0 points, 4.6 assists, 2.7 rebounds and 3.3 three-pointers in 29.7 minutes per game while shooting 50.0 percent from deep.